IE
NRIX icon

Israel Englander’s Nurix Therapeutics NRIX Stock Holding History

Israel Englander’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Sell
20,910
-525,387
-96% -$8.95M ﹤0.01% 4763
2026
Q1 		$8.47M Buy
546,297
+366,538
+204% +$6.08M ﹤0.01% 2340
2025
Q4 		$3.41M Sell
179,759
-1,344,200
-88% -$19.3M ﹤0.01% 3425
2025
Q3 		$14.1M Buy
1,523,959
+596,401
+64% +$6.19M 0.01% 2040
2025
Q2 		$10.6M Buy
927,558
+53,159
+6% +$574K 0.01% 2197
2025
Q1 		$10.4M Buy
874,399
+450,262
+106% +$7.53M 0.01% 2149
2024
Q4 		$7.99M Buy
424,137
+202,419
+91% +$4.64M ﹤0.01% 2389
2024
Q3 		$4.98M Sell
221,718
-377,905
-63% -$8.56M ﹤0.01% 2843
2024
Q2 		$12.5M Buy
599,623
+225,374
+60% +$3.51M 0.01% 1892
2024
Q1 		$5.5M Sell
374,249
-3,339
-0.9% -$35.9K ﹤0.01% 2766
2023
Q4 		$3.9M Buy
377,588
+89,431
+31% +$613K ﹤0.01% 3002
2023
Q3 		$2.26M Sell
288,157
-356,254
-55% -$3.25M ﹤0.01% 3440
2023
Q2 		$6.44M Buy
644,411
+182,819
+40% +$1.86M ﹤0.01% 2424
2023
Q1 		$4.1M Sell
461,592
-85,743
-16% -$894K ﹤0.01% 2781
2022
Q4 		$6.01M Sell
547,335
-192,590
-26% -$2.32M ﹤0.01% 2656
2022
Q3 		$9.64M Sell
739,925
-72,003
-9% -$1.14M 0.01% 2192
2022
Q2 		$10.3M Buy
811,928
+445,696
+122% +$5.05M 0.01% 2000
2022
Q1 		$5.13M Sell
366,232
-230,054
-39% -$4.08M ﹤0.01% 2912
2021
Q4 		$17.3M Buy
596,286
+359,403
+152% +$10.9M 0.01% 1582
2021
Q3 		$7.1M Sell
236,883
-189,103
-44% -$5.84M ﹤0.01% 2478
2021
Q2 		$11.3M Buy
425,986
+186,051
+78% +$5.46M 0.01% 1747
2021
Q1 		$7.46M Buy
239,935
+126,731
+112% +$4.79M 0.01% 2119
2020
Q4 		$3.72M Buy
+113,204
New +$3.75M ﹤0.01% 2727

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's NRIX Position: Q2 2026 in Review

Israel Englander reduced its Nurix Therapeutics (NRIX) stake by 96% in Q2 2026, selling an estimated $8.95M and leaving 20,910 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #4763.

Israel Englander first reported a position in NRIX in Q4 2020 and has held it in 23 quarters since. The position peaked at $17.3M in Q4 2021. 210 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Israel Englander held 20,910 shares of Nurix Therapeutics worth $507K as of Q2 2026.
  • Israel Englander sold 525,387 Nurix Therapeutics shares in Q2 2026, an estimated $8.95M.
  • Nurix Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4763 holding.
  • Israel Englander first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Israel Englander's Nurix Therapeutics position peaked at $17.3M in Q4 2021.
  • 210 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.